Analysts Set Zura Bio Limited (NASDAQ:ZURA) Target Price at $10.75

Shares of Zura Bio Limited (NASDAQ:ZURA) have been given an average rating of “Moderate Buy” by the six analysts that are currently covering the company, Marketbeat reports. One research analyst has rated the stock with a sell recommendation, one has issued a hold recommendation, three have given a buy recommendation and one has assigned a strong buy recommendation to the company. The average 1 year target price among brokers that have issued ratings on the stock in the last year is $10.75.

ZURA has been the topic of a number of recent research reports. Leerink Partnrs upgraded shares of Zura Bio to a “strong-buy” rating in a research report on Sunday, November 23rd. Chardan Capital reiterated a “buy” rating and set a $10.00 price objective on shares of Zura Bio in a research note on Friday, November 14th. Wall Street Zen cut shares of Zura Bio from a “hold” rating to a “sell” rating in a report on Sunday, November 16th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Zura Bio in a report on Tuesday, October 14th. Finally, HC Wainwright dropped their price target on Zura Bio from $3.00 to $2.00 and set a “neutral” rating on the stock in a research report on Tuesday, August 19th.

Zura Bio Stock Performance

NASDAQ:ZURA opened at $4.02 on Wednesday. The company has a market capitalization of $261.38 million, a price-to-earnings ratio of -6.18 and a beta of 0.24. Zura Bio has a one year low of $0.97 and a one year high of $4.68. The stock has a 50-day simple moving average of $3.80 and a 200 day simple moving average of $2.44.

Zura Bio (NASDAQ:ZURA) last announced its quarterly earnings data on Thursday, November 13th. The company reported ($0.21) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.19) by ($0.02). On average, equities research analysts forecast that Zura Bio will post -0.65 EPS for the current fiscal year.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently bought and sold shares of the company. JPMorgan Chase & Co. raised its stake in Zura Bio by 78.7% during the 2nd quarter. JPMorgan Chase & Co. now owns 4,659,951 shares of the company’s stock valued at $4,893,000 after acquiring an additional 2,052,732 shares in the last quarter. Boothbay Fund Management LLC bought a new position in shares of Zura Bio in the third quarter worth $3,568,000. ADAR1 Capital Management LLC increased its holdings in shares of Zura Bio by 34.9% during the first quarter. ADAR1 Capital Management LLC now owns 2,801,184 shares of the company’s stock valued at $3,614,000 after purchasing an additional 723,933 shares during the period. Allostery Investments LP increased its holdings in shares of Zura Bio by 44.2% during the first quarter. Allostery Investments LP now owns 2,329,384 shares of the company’s stock valued at $3,005,000 after purchasing an additional 714,258 shares during the period. Finally, Suvretta Capital Management LLC raised its stake in shares of Zura Bio by 12.6% during the third quarter. Suvretta Capital Management LLC now owns 5,472,891 shares of the company’s stock valued at $23,698,000 after purchasing an additional 611,952 shares in the last quarter. 61.14% of the stock is owned by institutional investors and hedge funds.

Zura Bio Company Profile

Zura Bio Limited, a clinical-stage biotechnology company, focuses on developing novel medicines for immune and inflammatory disorders. It develops Tibulizumab, an IgG-scFv bispecific dual-antagonist antibody engineered by the fusion of ixekizumab and tabalumab that neutralizes IL-17A and BAFF, which is in Phase 2 clinical trial development; ZB-168, a monoclonal antibody that binds and neutralizes the IL-7 receptor chain that impact on diseases driven by IL7 and thymic stromal lymphopoietin immune pathways; and Torudokimab, a monoclonal antibody that neutralizes IL33, which is in Phase 2 clinical trial development.